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Abstract
Objective We studied the role of the NC_000017.10:g.380
51348A[G (rs8067378) single nucleotide polymorphism
(SNP) located 9.5 kb downstream of gasdermin B
(GSDMB), in the development and progression of cervical
squamous cell carcinomas (SCC).
Methods Using high-resolution melting curve analysis, we
genotyped this SNP in patients with cervical SCC
(n = 486) and controls (n = 511) from the Polish Cau-
casian population. Logistic regression analysis was used to
adjust for the effect of confounders such as age, parity, oral
contraceptive use, tobacco smoking, and menopausal sta-
tus. The effect of this SNP on the expression of GSDMB
was studied by reverse transcription and quantitative real-
time polymerase chain reaction analysis of GSDMB tran-
script levels in SCC tissues.
Results For all patients with SCC, the p trend value cal-
culated for rs8067378 was statistically significant
(ptrend = 0.0019). The adjusted odds ratio for the G/G vs.
A/A genotype was 1.304 (95% confidence interval
1.080–1.574, p = 0.0057) and the adjusted odds ratio for
the G/A ? G/G vs. A/A genotype was 1.444 (95% confi-
dence interval 1.064–1.959, p = 0.0181). We also found a
significant association of the rs8067378 SNP with tumor
stages III, IV, and grade of differentiation G3, and with
parity, oral contraceptive use, smoking, and women of
postmenopausal age. We found increased GSDMB1 iso-
form transcripts in the cancerous and non-cancerous tissues
from carriers of the G allele vs. carriers of the A/A
genotype.
Conclusions The rs8067378 SNP variants may increase
the expression of GSDMB and the risk of the development




transition may upregulate transcription of GSDMB in
tumoral and non-tumoral cervical tissues.
This transition may be associated with increased
development and spread of cervical squamous cell
carcinoma cells to the surrounding tissues.
1 Introduction
Cervical cancer (CC) is one of the most common tumors in
women and remains one of the main causes of death among
women worldwide [1]. The precancerous state of cervical
intraepithelial neoplasia, which may progress to CC, is
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usually the result of persistent infection with one of the
oncogenic high-risk human papillomavirus (HPV) strains
[2]. HPV E6 and E7 oncoproteins impair the function of
p53 and pRb proteins and drive the cells to uncontrolled
proliferation [3]. Additionally, E6 and E7 oncoproteins
lead to chromosomal aberration [4]. It has been observed
that the most high-risk HPV virions are eliminated by the
hosts’ immune system and only a minority of infections
lead to a cervical lesion [5, 6]. These studies indicate that
long-term infection with high-risk HPV contributes to
cervical carcinogenesis; however, this further depends on
an individual’s genetic background [5, 6]. The risk factors
for CC also include multiparity, cigarette use, sexual his-
tory, abnormalities in the immune system, and environ-
mental pollutants [7–10]. Important risk factors for CC are
heritable genetic components, including a family history of
cancer, especially in first-degree relatives [11]. The
recently carried out genome-wide association studies
highlight the major histocompatibility complex region in
particular as being associated with cervical carcinogenesis
[12–14].
Additionally, genome-wide association studies in the
Chinese population have demonstrated invasive CC to be
associated with polymorphisms within two non-major
histocompatibility complex loci: among them was the
NC_000017.10:g.38051348A[G (rs8067378) single
nucleotide polymorphism (SNP) [13]. The products of
gasdermin B [GSDMB (OMIM *611221)] are the four
protein isoforms GSDMB1–4 [15]. It has been demon-
strated that the GSDMB protein may be linked with CC
development and progression [15]. We replicated the
prevalence of the rs8067378 SNP in patients with cervical
squamous cell carcinomas (SCCs) in the Polish Caucasian
population and we assessed the association of this SNP to
different stages and grades of differentiation. We also
evaluated the effect of rs8067378 genotypes on this gene’s
transcript isoform GSDMB1–4 levels in primary SCC and
non-cancerous tissues.
2 Patients and Methods
2.1 Study Population and Tissue Samples
The study population consisted of 486 patients with cer-
vical SCC, with stage and grade of differentiation assessed
by an experienced histopathologist based on the Interna-
tional Federation of Gynecology and Obstetrics classifica-
tion system and the World Health Organization (Table 1).
Patient data and primary cervical SCC tissue samples were
obtained from patients enrolled between October 2007 and
August 2015 at the Department of Radiotherapy of the
Greater Poland Cancer Center in Poznan´, Poland. The
control group consisted of 511 unrelated healthy female
volunteers selected during a medical examination at the
University Hospital, Clinic of Gynecological Surgery at
Poznan´ University of Medical Sciences (Table 1). Infor-
mation regarding a parity of at least one, oral contraceptive
use, active tobacco smoking at minimum within the last
12 months, and menopausal status was obtained as part of
the control and patient history.
The primary SCC tissue samples were obtained from 47
patients with a mean age of 51.6 ± 10.2 years and classi-
fied as stage III at the time of surgery. The non-cancerous
cervical tissue samples were obtained from 47 women with
Table 1 Clinical and demographic characteristics of patients with






Mean age (years)a ± SD 51.5 ± 9.7 51.8 ± 9.5















Never 58 (11.9) 63 (12.3) 0.849
Ever 428 (88.1) 448 (87.7)
Oral contraceptive pill use, n (%)
Never 263 (54.1) 289 (56.6) 0.438
Ever 223 (45.9) 222 (43.4)
Tobacco smoking, n (%)
Never 309 (63.6) 337 (65.9) 0.434
Ever 177 (36.4) 174 (34.1)
Menopausal status, n (%)
Premenopausal 171 (35.2) 197 (38.6) 0.271
Postmenopausal 315 (64.8) 314 (61.4)
HPV genotypes, n (%)
16 and 18 326 (67.1)
16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, and 68
368 (75.7)
HPV human papillomavirus virus, SD standard deviation
a Age at first diagnosis
b Chi-squared, p value
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a mean age of 51.4 ± 9.8 years and with uterine fibroids
undergoing uterine surgical resection in the Division of
Gynecological Surgery, Poznan´ University of Medical
Sciences, Poznan´, Poland. A portion of the tissue sample
was immediately snap frozen in liquid nitrogen and stored
at -80 C until RNA isolation. All the patients and con-
trols participating in the study were Caucasians from the
Wielkopolska area of Poland. Written consent was
obtained from all participating individuals. The study
procedures were approved by the Local Ethics Committee
of the Poznan´ University of Medical Sciences (Reference
no. of ethical approval: 1010/07).
2.2 Genotyping of the rs8067378 SNP
DNA was isolated from peripheral blood cells via a salting-
out procedure. The primers were designated employing
Oligo 7.6 software (DBA Oligo, Inc., Colorado Springs,
CO, USA). The rs8067378 polymorphism DNA fragment
(225 bp) was amplified using the primers forward 50
GAAAGAAGAGCACAGATAAAC 30 and reverse 50
CGGATGACTGGTGAAATAAGC 30. The rs8067378
SNP was then genotyped via high-resolution melting curve
analysis using HOT FIREPol EvaGreen (Solis BioDyne,
Tartu, Estonia) with a LightCycler 480 system (Roche
Diagnostics, Mannheim, Germany). The presence of this
SNP was reanalyzed by Sanger sequencing analyses of
randomly selected samples comprising 10% of the samples
from all of the participants. The concordance rate between
high-resolution melting and sequencing was equal to
100%.
2.3 Reverse Transcription and Quantitative Real-
Time Polymerase Chain Reaction Analysis
of GSDMB Transcript Levels in SCC and Non-
Cancerous Tissues
Frozen SCC and non-cancerous tissues were homogenized
and total RNA was isolated according to the method of
Chomczyn´ski and Sacchi [16]. RNA quality was deter-
mined spectrophotometrically using a BioPhotometer
from Eppendorf AG (Hamburg, Germany) and agarose gel
electrophoresis. RNA samples were treated with DNase I,
quantified, and reverse transcribed into complementary
DNA (cDNA) with the Moloney Murine Leukemia Virus
from Invitrogen (Life Technologies, Carlsbad, CA, USA)
[Online Resource 1].
Quantitative analysis of GSDMB1–4 cDNA isoforms
(Online Resource 1) was performed by Light Cycler480 II
Real-Time PCR System (Roche Diagnostics GmbH,
Mannheim, Germany), using SYBR Green I as the detec-
tion dye. GSDMB1–4 cDNA was quantified using the
relative quantification method with a calibrator. The
calibrator was prepared with a cDNA mix from all cDNA
samples and consecutive dilutions were used to create a
standard curve. For amplification, 1 lL of cDNA solution
was added to 9 lL of LightCycler 480 SYBR Green I
Master Mix (Roche Diagnostics GmbH, Mannheim, Ger-
many) and primers (Online Resource 1).
The quantity of the GSDMB1–4 transcript in each
sample was standardized by the geometric mean of refer-
ence transcript levels: hydroxymethylbilane synthase and
b-2-microglobulin. The polymerase chain reaction ampli-
fication efficiency for target and reference cDNA was
determined by different standard curves created by con-
secutive dilutions of the cDNA template mixture. The
GSDMB1–4 cDNA, hydroxymethylbilane synthase, and
b-2-microglobulin cDNA were amplified using the primer
pairs presented in Online Resource 1. The GSDMB mRNA
levels were expressed as multiples of these cDNA con-
centrations in the calibrator.
2.4 Data Analysis
The distinction in genotypic prevalence between the
patients and controls and their genotype deviation from the
Hardy–Weinberg equilibrium were evaluated using a v2
test. The polymorphism was tested for association with CC
incidence using the Cochran–Armitage p trend test (ptrend).
The v2 and Fisher exact tests were used to determine the
differences in genotypic distributions between the patients
and controls. The odds ratio (OR) and 95% confidence
intervals (CIs) were also calculated. A logistic regression
analysis was used to adjust for the effect of confounders
such as age, parity, oral contraceptive use, tobacco smok-
ing, and menopausal status. A p value of\0.05 was con-
sidered statistically significant. Statistical analysis of
comparing GSDMB1–4 isoform transcript levels between
the G/G vs. A/A and A/G vs. A/A genotype carriers was
evaluated by the Kruskal–Wallis test with either Dunn’s
post-hoc test or Tukey’s post-hoc test. Statistical analyses
were conducted using Statistica version 10, 2011 (Stat Soft,
Inc., Tulsa, OK, USA).
3 Results
3.1 Prevalence of the rs8067378 SNP Among all
Patients with SCC and Controls
The values for the v2 test of the Hardy–Weinberg equi-
librium were 0.329 and 0.181 for the patients and controls,
respectively. The statistical evaluation of the rs8067378
genotype prevalence in cases and controls are shown in
Table 2. For all patients with SCC, the ptrend value calcu-
lated for the rs8067378 transition was statistically
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Table 2 Prevalence of the rs8067378 polymorphism among patients with squamous cell carcinoma and controls
Genotype Patients (frequency) Controls (frequency) Odds ratio (95% CI) p valuea Adjusted p value ptrend
Odds ratio (95% CI)c
All
A/A 91 (0.19) 127 (0.25) Referent Referent 0.0019
G/G 138 (0.28) 108 (0.21) 1.783 (1.233–2.578) 0.002 1.304 (1.080–1.574) 0.0057
G/A 257 (0.53) 276 (0.54) 1.300 (0.9452–1.787) 0.1063 1.302 (0.944–1.794) 0.1069




A/A 34 (0.26) 127 (0.25) Referent Referent 0.5046
G/G 35 (0.26) 108 (0.21) 1.211 (0.7073–2.072) 0.4855 0.998 (0.760–1.311) 0.9906
G/A 63 (0.48) 276 (0.54) 0.8526 (0.5344–1.360) 0.5032 0.712 (0.417–1.217) 0.2137
G/A ? GG 98 (0.74) 384 (0.75) 0.9533 (0.6147–1.478) 0.8307 0.937 (0.597–1.469) 0.7751
MAFd 0.50 0.48
IIA ? IIB
A/A 32 (0.27) 127 (0.25) Referent Referent 0.8606
G/G 29 (0.24) 108 (0.21) 1.066 (0.6061–1.874) 0.8251 0.985 (0.733–1.324) 0.9202
G/A 59 (0.49) 276 (0.54) 0.8484 (0.5255–1.370) 0.5007 0.847 (0.524–1.371) 0.4988
G/A ? GG 88 (0.73) 384 (0.75) 0.9095 (0.5789–1.429) 0.6805 0.909 (0.577–1.432) 0.6802
MAFd 0.49 0.48
IIIA ? IIIB
A/A 23 (0.11) 127 (0.25) Referent Referent <0.0001
G/G 66 (0.32) 108 (0.21) 3.374 (1.967–5.788) <0.0001 1.674 (1.260–2.225) 0.0004
G/A 120 (0.57) 276 (0.54) 2.401 (1.466–3.932) 0.0004 2.180 (1.316–3.61) 0.0024
G/A ? GG 186 (0.89) 384 (0.75) 2.675 (1.659–4.312) <0.0001 2.696 (1.668–4.367) 0.0001
MAFd 0.60 0.48
IVA ? IVB
A/A 2 (0.08) 127 (0.25) Referent Referent 0.0452
G/G 8 (0.32) 108 (0.21) 4.704 (0.9776–22.631) 0.0501b 2.222 (0.990–4.990) 0.0518
G/A 15 (0.6) 276 (0.54) 3.451 (0.7773–15.323) 0.1081b NA NA




A/A 23 (0.23) 127 (0.25) Referent Referent 0.5261
G/G 24 (0.24) 108 (0.21) 1.227 (0.6555–2.297) 0.5219 1.069 (0.775–1.474) 0.6845
G/A 52 (0.52) 276 (0.54) 1.040 (0.6099–1.775) 0.8846 0.887 (0.486–1.617) 0.6943
G/A ? GG 76 (0.77) 384 (0.75) 1.093 (0.6576–1.816) 0.7318 1.036 (0.610–1.759) 0.8947
MAFd 0.49 0.48
G2
A/A 32 (0.21) 127 (0.25) Referent Referent 0.0829
G/G 43 (0.28) 108 (0.21) 1.580 (0.9350–2.670) 0.0861 1.254 (0.960–1.638) 0.0960
G/A 77 (0.51) 276 (0.54) 1.107 (0.6970–1.759) 0.6661 1.037 (0.641–1.677) 0.8829
G/A ? GG 120 (0.79) 384 (0.75) 1.240 (0.7998–1.923) 0.3353 1.218 (0.781–1.901) 0.3841
MAFd 0.54 0.48
G3
A/A 11 (0.10) 127 (0.25) Referent Referent 0.0004
G/G 34 (0.33) 108 (0.21) 3.635 (1.757–7.518) 0.0003 2.004 (1.305–3.078) 0.0014
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significant (ptrend = 0.0019). The logistic regression anal-
ysis, which adjusted for the effects of age, parity, oral
contraceptive use, tobacco smoking, and menopausal sta-
tus, also demonstrated a contribution of the rs8067378 SNP
to cervical SCC development (Table 2). We observed that
the G/G vs. A/A genotype is a risk factor of cervical SCC
with an adjusted OR of 1.304 (95% CI 1.080–1.574,
p = 0.0057). We observed the same risk effect of the
G/A ? G/G vs. A/A genotype, with an adjusted OR of
1.444 (95% CI 1.064–1.959, p = 0.0181). However, we
did not find an association with cervical carcinogenesis for
the G/A vs. A/A genotype, adjusted OR of 1.302 (95% CI
0.944–1.794, p = 0.1069).
3.2 Distribution of the rs8067378 SNP among SCC
Patients with Different Tumor Stage and Grade
of Differentiation
Stratified analyses revealed an association of the rs8067378
genotypes with tumor stages III, IV, and grade of differ-
entiation G3 (Table 2). The ptrend value calculated for the
rs8067378 SNP in cervical SCC patients with stages III and
IV was statistically significant (ptrend\ 0.0001 and
ptrend = 0.0452, respectively). Adjusting for the effect of
age, parity, oral contraceptive use, tobacco smoking, and
menopausal status in patients with stages III, the logistic
regression analysis demonstrated that the G/G vs. A/A
genotype is a risk factor of cervical carcinogenesis with an
adjusted OR of 1.674 (95% CI 1.260–2.225, p = 0.0004).
There was also a risk effect of SCC for the G/A vs. A/A
genotype, with an adjusted OR of 2.180 (95% CI
1.316–3.61, p = 0.0024) and for the G/G ? G/A vs. A/A
genotype, with an adjusted OR of 2.696 (95% CI
1.668–4.367, p = 0.0001) in stage III patients.
In patients with grade of differentiation G3, the ptrend
value calculated for the rs8067378 SNP was statistically
significant (ptrend = 0.0004). We found a risk effect of the
G/G vs. A/A genotype, with an adjusted OR of 2.004 (95%
CI 1.305–3.078, p = 0.0014) for the G/A vs. A/A geno-
type, with an adjusted OR of 2.346 (95% CI 1.180–4.666,
p = 0.0148), and for the G/G ? G/A vs. A/A genotype,
with an adjusted OR of 2.782 (95% CI 1.437–5.389,
p = 0.0024). However, the logistic regression analysis did
not show any association of the rs8067378 SNP with tumor
stage I, II, and IV and grade of differentiation G1, G2, and
GX. Moreover, there was no contribution of the rs8067378
SNP with HPV strains to either SCC or tumor stage I, II,
and IV and grade of differentiation G1, G2, and GX (data
not shown).
3.3 Distribution of the rs8067378 SNP among SCC
Patients and Controls with a History of Parity,
Oral Contraceptive Use, Tobacco Smoking,
or Menopausal Status
The stratified analysis for the rs8067378 polymorphism
revealed a risk role of this SNP among patients with a
positive history of parity, oral contraceptive use, smoking,
and among women of postmenopausal age (Table 3). The
age-adjusted OR for women with a history of parity for
G/G vs. A/A was 1.323 (95% CI 1.083–1.615, p = 0.0059)
and for G/G ? G/A vs. A/A was 1.484 (95% CI
1.071–2.055, p = 0.0174). The age-adjusted OR for
women with a history of oral contraceptive use for G/G vs.
Table 2 continued
Genotype Patients (frequency) Controls (frequency) Odds ratio (95% CI) p valuea Adjusted p value ptrend
Odds ratio (95% CI)c
G/A 59 (0.57) 276 (0.54) 2.468 (1.254–4.858) 0.0073 2.346 (1.180–4.666) 0.0148
G/A ? GG 93 (0.89) 384 (0.75) 2.796 (1.450–5.391) 0.0015 2.782 (1.437–5.389) 0.0024
MAFd 0.61 0.48
Gx
A/A 25 (0.19) 127 (0.25) Referent Referent 0.0532
G/G 37 (0.28) 108 (0.21) 1.740 (0.9855–3.074) 0.0545 1.232 (0.914–1.660) 0.1692
G/A 69 (0.53) 276 (0.54) 1.270 (0.7675–2.101) 0.3514 0.672 (0.369–1.226) 0.1940
G/A ? GG 106 (0.81) 384 (0.75)) 1.402 (0.8678–2.266) 0.1658 1.167 (0.708–1.927) 0.5436
MAFd 0.54 0.48
Significant results are highlighted in bold font
CI confidence interval, NA the number of genotypes is too small, therefore the logistic regression does not apply
a v2 test
b Fisher exact test
c Odds ratios were adjusted by age, parity, oral contraceptive use, tobacco smoking, and menopausal status
d Minor allele frequency
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AA was 1.376 (95% CI 1.043–1.816, p = 0.0232). The
age-adjusted OR for women with a history of tobacco
smoking for G/G vs. AA was 1.666 (95% CI 1.195–2.322,
p = 0.0024) and for G/G ? G/A vs. A/A was 1.958 (95%
CI 1.133–3.384, p = 0.0157). The age-adjusted OR among
women of postmenopausal age for G/G vs. A/A was 1.334
(95% CI 1.059–1.679, p = 0.0138).
3.4 Effect of the rs8067378 Polymorphism
on GSDMB1–4 Transcript Isoform Levels
in SCC and Non-Cancerous Tissues
We observed statistically significant increased GSDMB1
isoform transcript levels in the SCC cervical tissues from
carriers of the GG vs. A/A (p = 0.00001) and G/A vs. A/A
(p = 0.017) (Fig. 1a). We also found a statistically sig-
nificant increase in the GSDMB1 transcript levels in the
non-cancerous cervical tissues from carriers of the GG vs.
AA (p = 0.000001) and G/A vs. A/A (p = 0.033)
(Fig. 1b). There were also statistically significant increased
GSDMB2 and 3 isoform transcripts in the SCC cervical
tissues from carriers of the G/G vs A/A genotype
(p = 0.010, p = 0.035, respectively) (Fig. 1a).
However, we did not find significant differences in
GSDMB2 and 3 isoform transcript levels in the SCC cer-
vical tissues for the GA vs. AA genotype (Fig. 1a). There
were also no significant differences in GSDMB2 and 3
isoform transcript levels in non-cancerous cervical tissues
from carriers of the G allele as compared with carriers of
the A/A genotype (Fig. 1b). We also did not find significant
differences in GSDMB4 isoform transcript levels in SCC
cervical tissues and non-cancerous cervical tissues from
carriers of the G allele as compared with carriers of the
A/A genotype (Fig. 1b).
4 Discussion
The GSDMB gene is located at 17q21.2, a region that
contains the ERBB2 gene, and is frequently amplified in
cancers [17–19]. GSDMB expression is driven by two
promoters: the cellular promoter and the Long Terminal
Repeats-derived promoter [20–22]. The studied
NC_000017.10:g.38051348A[G (rs8067378) SNP is situ-
ated 9.5 kb downstream of the GSDMB, in a region sug-
gested to be a functional polymorphism as part of the




Patients Controls Adjusted odds
ratio (95% CI)
p value Adjusted odds
ratio (95% CI)
p value
Genotype Ever Never Ever Never Ever Never
Parity
A/A 79 12 112 15 Referent Referent
G/A 228 29 241 35 1.347 (0.956–1.897) 0.0881 1.129 (0.443–2.878) 0.7954
G/G 121 17 95 13 1.323 (1.083–1.615) 0.0059 1.289 (0.752–2.209) 0.3447
G/A ? G/G 349 46 336 48 1.484 (1.071–2.055) 0.0174 1.274 (0.526–3.085) 0.5876
Oral contraceptive use
A/A 41 50 56 71 Referent Referent
G/A 116 141 119 157 1.558 (0.944–2.573) 0.0818 1.314 (0.853–2.024) 0.2145
G/G 66 72 47 61 1.376 (1.043–1.816) 0.0232 1.278 (0.991–1.648) 0.0571
G/A ? G/G 182 213 166 218 1.589 (1.001–2.523) 0.0509 1.407 (0.934–2.121) 0.1018
Smoking
A/A 28 63 43 84 Referent Referent
G/A 90 167 94 182 1.667 ().933–2.976) 0.0829 1.220 (0.826–1.803) 0.3169
G/G 59 79 37 71 1.666 (1.195–2.322) 0.0024 1.196 (0.948–1.508) 0.1288
G/A ? G/G 149 246 131 253 1.958 (1.133–3.384) 0.0157 1.306 (0.900–1.896) 0.1586
Menopausal status
Premenopausal Postmenopausal Premenopausal Postmenopausal Premenopausal Postmenopausal
A/A 27 64 47 80 Referent Referent
G/A 105 152 108 168 1.739 (1.000–3.023) 0.0501 1.197 (0.800–1.791) 0.3796
G/G 39 99 42 66 1.381 (0.981–1.939) 0.0606 1.334 (1.059–1.679) 0.0138
G/A ? G/G 144 251 150 234 1.662 (0.977–2.826) 0.0602 1.367 (0.938–1.992) 0.1035
CI confidence interval
All p values were adjusted by age. Significant results are highlighted in bold font
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transcriptional regulatory element and/or modulator of
chromatin structure in this domain [23, 24].
Human GSDMB is transcribed in proliferating normal
epithelial cells and is overexpressed in various carcinomas,
including those of the esophagus, breast, liver, stomach,
colon, and uterine cervix [15, 25–29]. Sun et al. reported
that GSDMB may also contribute to the development and
progression of uterine CC [15]. They demonstrated that the
GSDMB protein was present at increased levels in CC
tissues as compared with the adjacent cancerous tissues and
corresponding normal tissues [15].
We found the rs8067378 SNP to be a risk factor of
cervical SCC among all patients from the studied Polish
Caucasian population. To date, the minor allele G of
Fig. 1 Effect of the GSDMB
rs8067378 polymorphism on
GSDMB1–4 isoform transcript
levels in cancerous cervical
tissues (a) and non-cancerous
tissues (b). Frozen tissue was
homogenized, followed by total
RNA isolation. Quantitative
analyses of GSDMB transcript
levels were performed by
quantitative real-time
polymerase chain reaction using
the SYBR Green I system. The
quantity of GSDMB transcript
levels in each sample was
standardized by the geometric
mean of references using
hydroxymethylbilane synthase
and b-2-microglobulin cDNA
levels. Kruskal–Wallis test with
aDunn’s post-hoc or bTukey’s
post-hoc test. GSDMB
gasdermin B
Gasdermin B Variants in the Development and Progression of Cervical SCC 205
rs8067378 has been found to be a significant risk factor for
cervical carcinogenesis in Han Chinese and Japanese
populations [13, 29].
We also observed that the rs8067378 polymorphism was
associated with stages III and IV of cervical SCC. This
suggests that there is a role of the G variant of rs8067378 in
the increased extension and spread of malignant cells to
neighboring tissues. In our studies, the rs8067378 variant
was also observed to be associated with differentiation
grade G3, which is prone to grow rapidly and spread faster
than lower-grade cancerous cells. Our findings are similar
to the recent replication study in a Japanese population, in
which the authors demonstrated that Japanese women with
the rs8067378 GG genotype belong to a high-risk group for
invasive CC [30].
Moreover, there was an increased risk of cervical car-
cinogenesis for the rs8067378 SNP in patients with a
positive history of parity, oral contraceptive use, smoking,
and women of postmenopausal age. This is consistent with
literature data indicating the causative influence of preg-
nancy, oral contraceptive use, tobacco smoking, and post-
menopausal age in cervical carcinogenesis [7–10].
The rs8067378 SNP has also been associated with the
development of asthma [24, 31, 32]. Functional studies
conducted for the rs8067378 SNP demonstrated reduced
expression of GSDMB for the G gene variant of rs8067378
in human bronchial epithelial and bronchial alveolar lavage
cells from patients with asthma [24]. In contrast, we found
significantly upregulated GSDMB1 isoform transcript levels
in both the cervical SCC and non-cancerous tissues from
carriers of the G allele as compared with carriers of the A/A
genotype. Additionally, we observed significantly increased
GSDMB2–3 isoform transcript levels in the cervical SCC
tissue for carriers of the G/G vs. A/A genotype. These dis-
crepancies may be owing to the use of different quantitate
assays and analyses of different GSDMB isoform transcripts
between the asthma study [24] and ours. These may also
have resulted from distinct transcription and epigenetic
factors regulating the expression of GSDMB in lung tissues
and cancerous and non-cancerous cervical tissues.
The increased expression of GSDMB for carriers of the
rs8067378 G gene variant confirm the observation of Sun
et al. They demonstrated that ectopic GSDMB expression
augmented the growth of CC cells in vitro, whereas
silencing the endogenous expression of GSDMB reduced
cancer cell proliferation [15].
5 Conclusions
Our genetic study is the first to report that the rs8067378
polymorphism can be a risk factor for cervical carcino-
genesis in a Caucasian cohort. Moreover, we observed that
the rs8067378 G variant upregulated the expression of
GSDMB, which was associated with increased growth and
spread of cancer cells to the surrounding tissues. However,
our study contains some limitation, for instance, one
Caucasian cohort with a relatively small sample size. This
study is also limited to one tested SNP. To achieve full
gene coverage, a number of other tag SNP needed to be
covered in this study. Other SNPs not included in this study
could account for alternation of GSDMB expression.
Therefore, our genetic study should be replicated for
rs8067378 and a number of other tag SNPs covering
GSDMB in other independent ethnicities.
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